Australia's Mesoblast at 4-yr high on US FDA nod for cell therapy

Mesoblast

19/12/2024 02:12

** Shares of Mesoblast  MSB.AX  rise as much as 46% to
A$2.890, their highest since Dec. 16, 2020
    ** Stock posts its biggest intraday percentage rise since
April 2
    ** Drug developer says U.S. Food and Drug Administration
approved co's cell therapy for graft-versus-host disease
    ** About 28.1 mln shares change hands, compared with the
30-day average volume of around 6.3 mln
    ** Stock up over 825% YTD, including session's move



 (Reporting by Aaditya Govind Rao in Bengaluru)
 ((Aaditya.govindrao@thomsonreuters.com;))